AstraZeneca on hindsight in the valuation of intangibles
The OECD is considering the use of hindsight when tax authorities are assessing hard-to-value intangibles (HTVI). Ian Brimicombe, VP of corporate finance at AstraZeneca in the UK, discusses the impact on taxpayers.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: